Abstract
Abstract
Vaccination against retroviruses is a challenge because of their ability to stably integrate into the host genome, undergo long-term latency in a proportion of infected cells and thereby escape immune response. Since clearance of the virus is almost impossible once infection is established, the primary goal is to achieve sterilizing immunity. Besides efficacy, safety is the major issue since vaccination has been associated with increased infection or reversion to pathogenicity. In this review, we discuss the different issues that we faced during the development of an efficient vaccine against bovine leukemia virus (BLV). We summarize the historical failures of inactivated vaccines, the efficacy and safety of a live-attenuated vaccine and the economical constraints of further industrial development.
Publisher
Springer Science and Business Media LLC
Subject
Infectious Diseases,Virology
Reference47 articles.
1. Barez PY, de Brogniez A, Carpentier A, Gazon H, Gillet N, Gutierrez G, et al. Recent advances in BLV research. Viruses. 2015;7:6080–8.
2. Gillet N, Florins A, Boxus M, Burteau C, Nigro A, Vandermeers F, et al. Mechanisms of leukemogenesis induced by bovine leukemia virus: prospects for novel anti-retroviral therapies in human. Retrovirology. 2007;4:18.
3. Aida Y, Murakami H, Takahashi M, Takeshima S-N. Mechanisms of pathogenesis induced by bovine leukemia virus as a model for human T-cell leukemia virus. Front Microbiol. 2013;4:328.
4. Burny A, Bruck C, Cleuter V, Couez D, Deschamps J, Ghysdael J, et al. Bovine Leukemia Virus, a versatile agent with various pathogenic effects in various animal species. Cancer Res. 1985;45(suppl):4578–83.
5. Norby B, Bartlett PC, Byrem TM, Erskine RJ. Effect of infection with bovine leukemia virus on milk production in Michigan dairy cows. J Dairy Sci. 2016;99:1–10.
Cited by
18 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献